Post-Traumatic Stress Disorder Therapeutics Global Market Report 2025

Description

Post-traumatic stress disorder (PTSD) therapeutics encompass treatments designed to address PTSD, a mental health condition that arises from experiencing or witnessing traumatic events. These treatments aim to enhance cognitive functioning, promote physical activity, and help patients regain a sense of control over their lives. Approaches to treating PTSD include medication, various therapies, self-care strategies, and nutritional support.

Key drugs utilized in post-traumatic stress disorder therapeutics encompass antidepressants, anti-anxiety medications, antihypertensive drugs, monoamine oxidase inhibitors (MAOIs), antipsychotics or second-generation antipsychotics (SGAs), beta-blockers, and others (including benzodiazepines and others). Antidepressants, a specific class of drugs, are employed to manage addictions and address conditions such as major depressive disorder, anxiety disorders, and chronic pain. The therapeutic interventions are administered across diverse age groups, including pediatric, geriatric, and adult populations, and are utilized by various end-users, including mental health centers, hospitals, outpatient clinics, and other healthcare facilities.

The post-traumatic stress disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed sulfuric acid market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This sulfuric acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The post-traumatic stress disorder therapeutics market size has grown steadily in recent years. It will grow from $1.14 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to increased awareness, trauma incidence, government initiatives, advancements in diagnostic tools, stigma reduction, psychological support programs, veteran healthcare focus.

The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.38 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to expanded access to mental health services, government mental health policies, biological and neurological research, PTSD in non-military populations, crisis response planning. Major trends in the forecast period include integration of digital therapeutics, advancements in pharmacological treatments, neurostimulation and brain stimulation techniques, psychedelic-assisted therapy, and collaborative research initiatives.

The increasing prevalence of post-traumatic stress disorder (PTSD) cases worldwide is anticipated to drive the growth of the PTSD therapeutics market in the future. PTSD is a condition that develops in individuals who have experienced a frightening, shocking, or dangerous event. Treatments for PTSD, including psychotherapy and medication, can help individuals regain a sense of control over their lives. For example, in March 2024, the Ministry of Defence (MoD) Department of Community Mental Health (DCMH), a UK-based organization that provides mental health services to active personnel and reservists, reported that the number of armed forces members undergoing initial PTSD assessments by a specialist mental health clinician rose from 266 cases in 2022 to 320 cases in 2023, indicating a significant increase in reported cases. Therefore, the rising burden of PTSD cases is fueling the growth of the PTSD therapeutics market.

The increasing incidence of mental health issues is projected to contribute to the expansion of the post-traumatic stress disorder (PTSD) therapeutic market. Mental health issues encompass a broad spectrum of conditions affecting an individual's thinking, perceptions, feelings, and behaviors. Therapeutics for PTSD address mental health issues through a combination of psychotherapy, medication, and other interventions. According to a 2022 survey by the House of Commons Library, 18.0% of children aged 7-16 were identified with a probable mental disorder in 2022, with an expected rise to 25.7% in 2022. Consequently, the growing prevalence of mental health issues is a key factor driving the growth of the post-traumatic stress disorder (PTSD) therapeutic market.

Strategic collaborations, funding, and investments have emerged as a prominent trend in the post-traumatic stress disorder therapeutics market. Major companies in the market are forming strategic collaborations and investing in various initiatives to fortify their positions. In January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University secured over $1.9 million for a study on the effectiveness of MDMA-assisted psychological treatment for alcohol use disorder (AUD) and PTSD. This initiative, part of the Medical Research Future Fund (MRFF), is one of seven clinical studies aiming to evaluate the potential of combination medicines for treating severe mental disorders.

Major companies in the post-traumatic stress disorder (PTSD) therapeutics market are concentrating on developing advanced technological devices, such as self-neuromodulation devices, to improve patient outcomes and offer alternative solutions to traditional therapies. These self-neuromodulation devices aim to enhance PTSD treatment by integrating computer simulations with EEG technology, enabling patients to gain control over amygdala activity, which is often hyperactive in individuals with PTSD. This approach provides complementary therapy alongside conventional treatments. For example, in January 2024, GrayMatters Health, a US-based health technology company, launched Prism for PTSD, the first FDA-approved self-neuromodulation device designed specifically for treating PTSD in the U.S. The device utilizes a combination of computer simulations and an EEG headset to create an immersive environment that helps individuals regulate amygdala-related biomarker activity associated with PTSD. The core technology behind Prism for PTSD is the digital EEG-fMRI-Pattern (EFP) biomarker, which is the first of its kind to monitor activity in specific brain areas. Developed using advanced statistical models, this technology synchronizes fMRI data from the amygdala with EEG readings. The therapy specifically targets an amygdala-based biomarker, addressing research findings that link PTSD to increased amygdala activity.

In June 2023, Stella Center, a U.S.-based provider of PTSD treatment, acquired the U.S. assets of Field Trip Health for an undisclosed amount. This acquisition is expected to expand Stella's range of advanced treatments, including Field Trip Health's outcomes data, research, technology stack, clinics, and leadership. Field Trip Health, a Canada-based provider of psychedelic-assisted therapies for mental health conditions, including PTSD, is the focus of this strategic move.

Major companies operating in the post-traumatic stress disorder therapeutics market include Pfizer Inc., GlaxoSmithKline plc, Bionomics Limited, Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, AstraZeneca plc, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Compass Pathways plc, Boehringer Ingelheim International GmbH, Halucenex Life Sciences Inc., Bionorica SE, MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Takeda Pharmaceutical Company Limited, Merck KGaA, Jazz Pharmaceuticals plc

North America was the largest region in the post-traumatic stress disorder therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the post-traumatic stress disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Post-Traumatic Stress Disorder Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on post-traumatic stress disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for post-traumatic stress disorder therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The post-traumatic stress disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Antidepressants; Anti-Anxiety; Antihypertensive; Monoamine Oxidase (MAOs); Antipsychotics Or Second Generation Antipsychotics (SGOs); Beta-Blockers; Other Classes
2) By Age Group: Pediatric; Geriatric; Adult
3) By End User: Mental Health Center; Hospitals; Outpatient Clinics; Other End Users
Subsegments:
1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
2) By Anti-Anxiety: Benzodiazepines; Buspirone
3) By Antihypertensive: Prazosin; Clonidine
4) By Monoamine Oxidase Inhibitors (MAOs): Traditional MAOIs; Reversible MAOIs
5) By Antipsychotics (Second Generation Antipsychotics - SGOs): Risperidone; Quetiapine
6) By Beta-Blockers: Propranolol; Atenolol
7) By Other Classes: Mood Stabilizers; Adjunctive Therapies
Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Bionomics Limited; Otsuka Pharmaceutical Co Ltd.; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23665

1. Executive Summary

2. Post-Traumatic Stress Disorder Therapeutics Market Characteristics

3. Post-Traumatic Stress Disorder Therapeutics Market Trends And Strategies

4. Post-Traumatic Stress Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Post-Traumatic Stress Disorder Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Post-Traumatic Stress Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Post-Traumatic Stress Disorder Therapeutics Market Growth Rate Analysis
5.4. Global Post-Traumatic Stress Disorder Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Post-Traumatic Stress Disorder Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Post-Traumatic Stress Disorder Therapeutics Total Addressable Market (TAM)

6. Post-Traumatic Stress Disorder Therapeutics Market Segmentation

6.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antidepressants
Anti-Anxiety
Antihypertensive
Monoamine Oxidase (MAOs)
Antipsychotics Or Second Generation Antipsychotics (SGOs)
Beta-Blockers
Other Classes
6.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediartic
Geriatric
Adult
6.3. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mental Health Center
Hospitals
Outpaitent Clinics
Other End Users
6.4. Global Post-Traumatic Stress Disorder Therapeutics Market, Sub-Segmentation Of Antidepressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
6.5. Global Post-Traumatic Stress Disorder Therapeutics Market, Sub-Segmentation Of Anti-Anxiety, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Benzodiazepines
Buspirone
Forklift Pneumatic Tires
6.6. Global Post-Traumatic Stress Disorder Therapeutics Market, Sub-Segmentation Of Antihypertensive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prazosin
Clonidine
6.7. Global Post-Traumatic Stress Disorder Therapeutics Market, Sub-Segmentation Of Monoamine Oxidase Inhibitors (MAOs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Traditional MAOIs
Reversible MAOIs
6.8. Global Post-Traumatic Stress Disorder Therapeutics Market, Sub-Segmentation Of Antipsychotics (Second Generation Antipsychotics - SGOs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Risperidone
Quetiapine

7. Post-Traumatic Stress Disorder Therapeutics Market Regional And Country Analysis

7.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market

8.1. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Post-Traumatic Stress Disorder Therapeutics Market

9.1. China Post-Traumatic Stress Disorder Therapeutics Market Overview
9.2. China Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Post-Traumatic Stress Disorder Therapeutics Market

10.1. India Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Post-Traumatic Stress Disorder Therapeutics Market

11.1. Japan Post-Traumatic Stress Disorder Therapeutics Market Overview
11.2. Japan Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Post-Traumatic Stress Disorder Therapeutics Market

12.1. Australia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Post-Traumatic Stress Disorder Therapeutics Market

13.1. Indonesia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Post-Traumatic Stress Disorder Therapeutics Market

14.1. South Korea Post-Traumatic Stress Disorder Therapeutics Market Overview
14.2. South Korea Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Post-Traumatic Stress Disorder Therapeutics Market

15.1. Western Europe Post-Traumatic Stress Disorder Therapeutics Market Overview
15.2. Western Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Post-Traumatic Stress Disorder Therapeutics Market

16.1. UK Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Post-Traumatic Stress Disorder Therapeutics Market

17.1. Germany Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Post-Traumatic Stress Disorder Therapeutics Market

18.1. France Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Post-Traumatic Stress Disorder Therapeutics Market

19.1. Italy Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Post-Traumatic Stress Disorder Therapeutics Market

20.1. Spain Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market

21.1. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market Overview
21.2. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Post-Traumatic Stress Disorder Therapeutics Market

22.1. Russia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Post-Traumatic Stress Disorder Therapeutics Market

23.1. North America Post-Traumatic Stress Disorder Therapeutics Market Overview
23.2. North America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Post-Traumatic Stress Disorder Therapeutics Market

24.1. USA Post-Traumatic Stress Disorder Therapeutics Market Overview
24.2. USA Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Post-Traumatic Stress Disorder Therapeutics Market

25.1. Canada Post-Traumatic Stress Disorder Therapeutics Market Overview
25.2. Canada Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Post-Traumatic Stress Disorder Therapeutics Market

26.1. South America Post-Traumatic Stress Disorder Therapeutics Market Overview
26.2. South America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Post-Traumatic Stress Disorder Therapeutics Market

27.1. Brazil Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Post-Traumatic Stress Disorder Therapeutics Market

28.1. Middle East Post-Traumatic Stress Disorder Therapeutics Market Overview
28.2. Middle East Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Post-Traumatic Stress Disorder Therapeutics Market

29.1. Africa Post-Traumatic Stress Disorder Therapeutics Market Overview
29.2. Africa Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Post-Traumatic Stress Disorder Therapeutics Market Competitive Landscape And Company Profiles

30.1. Post-Traumatic Stress Disorder Therapeutics Market Competitive Landscape
30.2. Post-Traumatic Stress Disorder Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bionomics Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Post-Traumatic Stress Disorder Therapeutics Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Tonix Pharmaceuticals Holding Corp.
31.3. Freespira Inc.
31.4. MicroTransponder Inc.
31.5. Compass Pathways plc
31.6. Boehringer Ingelheim International GmbH
31.7. Halucenex Life Sciences Inc.
31.8. Bionorica SE
31.9. MAPS Europe BV
31.10. Hoffmann-La Roche Ltd.
31.11. Praxis Precision Medicines Inc.
31.12. H Lundbeck A/S
31.13. Johnson & Johnson
31.14. Sanofi SA
31.15. Takeda Pharmaceutical Company Limited

32. Global Post-Traumatic Stress Disorder Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Post-Traumatic Stress Disorder Therapeutics Market

34. Recent Developments In The Post-Traumatic Stress Disorder Therapeutics Market

35. Post-Traumatic Stress Disorder Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Post-Traumatic Stress Disorder Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Post-Traumatic Stress Disorder Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Post-Traumatic Stress Disorder Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer